Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Ardelyx

< Previous 1 2 3 4 Next >
Ardelyx Reports Progress of Development Programs
Ardelyx announces positive results from End-of-Phase 2 meeting with the FDA; the ongoing clinical trial evaluating tenapanor for the treatment of hyperphosphatemia for ESRD patients on dialysis may... 
Tickers ARDX
From PR Newswire
Ardelyx Appoints Robert Bazemore to Its Board of Directors
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Robert Bazemore joined the Company's Board of... 
Tickers ARDX
From PR Newswire
Ardelyx to Present at 2016 BIO International Convention
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Jeremy S. Caldwell, Ph.D., Executive Vice President... 
Tickers ARDX
From PR Newswire
Ardelyx Reports First Quarter 2016 Financial Results
Conference Call and Webcast Today at 4:30 p.m. ET 
Tickers ARDX
From PR Newswire
Ardelyx to Report First Quarter 2016 Financial Results on May 9, 2016
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report first quarter 2016 financial results... 
Tickers ARDX
From PR Newswire
Ardelyx Reports Fourth Quarter and Full-Year 2015 Financial Results
Three Late-Stage Clinical Trials for Tenapanor Initiated in 4Q2015 
Tickers ARDX
From PR Newswire
Ardelyx to Report Fourth Quarter and Full Year 2015 Financial Results on March 4th, 2016
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report its financial results for the fourth... 
Tickers ARDX
From PR Newswire
Ardelyx to Present at the 2016 Leerink Partners Global Healthcare Conference
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and renal diseases, today announced that Mike Raab, President and Chief Executive Officer, and David... 
Tickers ARDX
From PR Newswire
Ardelyx Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the completion of its previously announced underwritten... 
Tickers ARDX
From PR Newswire
Ardelyx Announces Pricing of Public Offering of Common Stock
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the pricing of an underwritten public offering of... 
Tickers ARDX
From PR Newswire
Ardelyx Announces Proposed Public Offering of Common Stock
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it has commenced an underwritten public offering of... 
Tickers ARDX
From PR Newswire
Ardelyx Reports Positive Clinical Results of RDX022 for the Treatment of Hyperkalemia
RDX022, Ardelyx's proprietary potassium binder, demonstrates clinically relevant fecal potassium binding in a pharmacodynamic study in healthy volunteers, supporting Phase 3 clinical plans 
Tickers ARDX
From PR Newswire
Ardelyx Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Executive Vice President and Chief Medical Officer
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Paul Korner, MD, MBA, joined the Company in a newly... 
Tickers ARDX
From PR Newswire
Ardelyx Reports Third Quarter 2015 Financial Results
Two key clinical development programs accelerated, tenapanor in IBS-C and RDX022 in hyperkalemia 
Tickers ARDX
From PR Newswire
Ardelyx to Report Third Quarter 2015 Financial Results on November 12, 2015
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report third quarter 2015 financial results... 
Tickers ARDX
From PR Newswire
Ardelyx Announces Upcoming Presentations for Tenapanor at the American Society of Nephrology's Kidney Week Meeting 2015
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced nonclinical and clinical data for tenapanor, the... 
Tickers ARDX
From PR Newswire
Ardelyx Appoints William Bertrand, Jr. to Its Board of Directors
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that William Bertrand, Jr., joined the Company's Board of... 
Tickers ARDX
From PR Newswire
Ardelyx to Present Phase 2 Data for Tenapanor in IBS-C Patients at the 2015 American College of Gastroenterology Annual Meeting
Sustained Response Results to Be Featured in Poster Presentation 
Tickers ARDX
From PR Newswire
Ardelyx Regains NaP2b Program from Sanofi
Allows Ardelyx to conduct further research on NaP2b and the complexities of phosphate transport and management 
Tickers ARDX
From PR Newswire
Ardelyx Reports Second Quarter 2015 Financial Results
Conference Call and Webcast Today at 8:00 a.m. ET 
Tickers ARDX
From PR Newswire
Ardelyx to Report Second Quarter 2015 Financial Results on August 12, 2015
Tickers ARDX
From PR Newswire
Ardelyx to Present at the 2015 Wedbush PacGrow Healthcare Conference
Tickers ARDX
From PR Newswire
Ardelyx to Provide Updates on Research and Development Programs at Today's Inaugural R&D Day in New York City
Tenapanor development plans will be presented along with new data demonstrating sustained response in IBS-C 
Tickers ARDX AZN
From PR Newswire
Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015
Tickers ARDX
From PR Newswire
Ardelyx to Present at the 2015 JMP Securities Life Sciences Conference
Tickers ARDX
From PR Newswire
Ardelyx Regains Worldwide Development and Commercialization Rights for Its Late-Stage Development Candidate, Tenapanor, and Related Portfolio of NHE3 Compounds
Ardelyx to Initiate a Phase 3 Clinical Program in IBS-C Patients in the Fourth Quarter of 2015 
Tickers ARDX AZN AZN
From PR Newswire
Ardelyx to Raise $77.8 Million in a Private Placement and Announces New Product Candidate for the Treatment of Hyperkalemia to Begin Clinical Development in Mid-2015
Ardelyx to Pursue an Accelerated 505b(2) Regulatory Pathway for RDX022 with Initiation of Phase 3 Program to Begin as Early as Second Half 2016 
Tickers ARDX
From PR Newswire
Ardelyx Presents Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients at Digestive Disease Week 2015
Tickers ARDX
From PR Newswire
Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors
Tickers ARDX
From PR Newswire
Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014
Tickers ARDX AZN AZN
From PR Newswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.